Yan‐Yan Li

Yan‐Yan Li

Auto-generated profile, based on publicly available information

Yan‐Yan Li

Department of Ultrasound, Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
YLYan‐Yan Li
Yan‐Yan Li
CYChun Yang
Chun Yang
PZPingting Zhou
Pingting Zhou
SZShijie Zhang
Shijie Zhang
YYYuan Yao
Yuan Yao
DLDong Li
Dong Li

28 November 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
YSYe‐Min Shi
Ye‐Min Shi
YLYan‐Yan Li
Yan‐Yan Li
JLJia‐Yun Lin
Jia‐Yun Lin
LZLei Zheng
Lei Zheng
YZYi-Ming Zhu
Yi-Ming Zhu
JHJian Huang
Jian Huang

10 April 2021 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
FZFang Zhao
Fang Zhao
SWShuangyan Wang
Shuangyan Wang
YLYan Li
Yan Li
JWJin Wang
Jin Wang
YWYujing Wang
Yujing Wang
ZCZhengyu Cao
Zhengyu Cao

20 December 2021 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
WCWeiyang Cai
Weiyang Cai
WBWenming Bao
Wenming Bao
SCShengwei Chen
Shengwei Chen
YYYan Yang
Yan Yang
YLYanyan Li
Yanyan Li
Background: Pancreatic cancer is one of the most common malignancies worldwide. In recent years, specific metabolic activities, which involves the development of tumor, caused wide public concern. In this study, we wish to explore the correlation between metabolism and progression of tumor. Methods: A retrospective analysis including 95 patients with pancreatic ductal adenocarcinoma (PDAC) and PDAC patients from The Cancer Genome Atlas (TCGA), the International Cancer Genome Consortium (ICGC), and The Gene Expression Omnibus (GEO) database were involved in our study. Multivariate Cox regression analysis was used to construct the prognosis model. The potential connection between metabolism and immunity of PDAC was investigated through a weighted gene co-expression network analysis (WGCNA). 22 types of Tumor-infiltrating immune cells (TIICs) between high-risk and low-risk groups were estimated through CIBERSORT. Moreover, the potential immune-related signaling pathways between high-risk and low-risk groups were explored through the gene set enrichment analysis (GSEA). The role of key gene GMPS in developing pancreatic tumor was further investigated through CCK-8, colony-information, and Transwell. Results: The prognostic value of the MetS factors was analyzed using the Cox regression model, and a clinical MetS-based nomogram was established. Then, we established a metabolism-related signature to predict the prognosis of PDAC patients based on the TCGA databases and was validated in the ICGC database and the GEO database to find the distinct molecular mechanism of MetS genes in PDAC. The result of WGCNA showed that the blue module was associated with risk score, and genes in the blue module were found to be enriched in the immune-related signaling pathway. Furthermore, the result of CIBERSORT demonstrated that proportions of T cells CD8, T cells Regulatory, Tregs NK cells Activated, Dendritic cells Activated, and Mast cells Resting were different between high-risk and low-risk groups. These differences are potential causes of different prognoses of PDAC patients. GSEA and the protein–protein interaction network (PPI) further revealed that our metabolism-related signature was significantly enriched in immune‐related biological processes. Moreover, knockdown of GMPS in PDAC cells suppressed proliferation, migration, and invasion of tumor cells, whereas overexpression of GMPS performed oppositely. Conclusion: The results shine light on fundamental mechanisms of metabolic genes on PDAC and establish a reliable and referable signature to evaluate the prognosis of PDAC. GMPS was identified as a potential candidate oncogene with in PDAC, which can be a novel biomarker and therapeutic target for PDAC treatment.

23 July 2021 in Research Square
Verified
Preprint
Open access
PDF file
WCWeiyang Cai
Weiyang Cai
WBWenming Bao
Wenming Bao
SCShengwei Chen
Shengwei Chen
YYYan Yang
Yan Yang
YLYan-Yan Li
Yan-Yan Li
Background: Pancreatic cancer is one of the most common malignancies worldwide. In recent years, specific metabolic activities, which involves the development of tumor, caused wide public concern. In this study, we wish to explore the correlation between metabolism and progression of tumor.Methods: A retrospective analysis including 95 patients with pancreatic ductal adenocarcinoma (PDAC) and PDAC patients from TCGA, ICGA, and GEO database were involved in our study. Multivariate Cox regression analysis was used to construct the prognosis model. The potential connection between metabolism and immunity of PDAC was investigated through WGCNA. 22 types of TIICs between high-risk and low-risk groups were estimated through CIBERSORT. Moreover, the potential immune-related signaling pathways between high-risk and low-risk groups were explored through the GSEA. The role of key gene GMPS in developing pancreatic tumor was further investigated through CCK-8, colony-information, and Transwell. Results: The prognostic value of the MetS factors was analyzed using the Cox regression model, and a clinical MetS-based nomogram was established. Then, we established a metabolism-related signature to predict the prognosis of PDAC patients based on the TCGA databases and was validated in the ICGC database and the GEO database to find the distinct molecular mechanism of MetS genes in PDAC. The result of WGCNA showed that the blue module was associated with risk score, and genes in the blue module were found to be enriched in the immune-related signaling pathway. Furthermore, the result of CIBERSORT demonstrated that proportions of T cells CD8, T cells Regulatory, Tregs NK cells Activated, Dendritic cells Activated, and Mast cells Resting were different between high-risk and low-risk groups. These differences are potential causes of different prognoses of PDAC patients. GSEA and the protein–protein interaction network (PPI) further revealed that our metabolism-related signature was significantly enriched in immune‐related biological processes. Moreover, knockdown of GMPS in PDAC cells suppressed proliferation, migration, and invasion of tumor cells, whereas overexpression of GMPS performed oppositely.Conclusion: The results shine light on fundamental mechanisms of metabolic genes on PDAC and establish a reliable and referable signature to evaluate the prognosis of PDAC. GMPS was identified as a potential candidate oncogene with in PDAC, which can be a novel biomarker and therapeutic target for PDAC treatment.